Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers

Glutamate neurotransmission is a prioritized target for antipsychotic drug development. Two metabotropic glutamate receptor 2/3 (mGluR2/3) agonists (pomaglumetad [POMA] and TS-134) were assessed in two Phase Ib proof of mechanism studies of comparable designs and using identical clinical assessments...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantrowitz, Joshua T., Grinband, Jack, Goff, Donald C., Lahti, Adrienne C., Marder, Stephen R., Kegeles, Lawrence S., Girgis, Ragy R., Sobeih, Tarek, Wall, Melanie M., Choo, Tse-Hwei, Green, Michael F., Yang, Yvonne S., Lee, Junghee, Horga, Guillermo, Krystal, John H., Potter, William Z., Javitt, Daniel C., Lieberman, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608251/
https://www.ncbi.nlm.nih.gov/pubmed/32403118
http://dx.doi.org/10.1038/s41386-020-0706-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608251/
https://www.ncbi.nlm.nih.gov/pubmed/32403118
http://dx.doi.org/10.1038/s41386-020-0706-z

Ejemplares similares